Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma

Figures & data

Table 1. Treatment schedule.

	Day 1	Day 2	Day 3	Day 4	Day 5
Etoposide (40 mg/m^2/day)	↓	↓	↓	↓
Cisplatin (25 mg/m^2/day, continuous)		↓	↓	↓	↓
Methylprednisolone (500 mg/body/day)	↓	↓	↓	↓	↓
Cytarabine (2000 mg/m^2/day)					↓
Ondansetron (4 mg)	↓	↓	↓	↓	↓

Table 2. Patient and treatment characteristics.

Variable		Dose of ESHAP
	All patients (n = 82)	Full dose (n = 61)	2/3 dose (n = 13)	1/2 dose (n = 8)
Median age, years [range]	63 [18–85]	60 [18–76]	71 [62–78]	79 [75–85]
Sex
Male	52	42	9	1
Female	30	19	4	7
Diagnosis
Diffuse large B-cell lymphoma	53	36	10	7
Hodgkin lymphoma	6	6	0	0
Peripheral T-cell lymphoma	5	5	0	0
Follicular lymphoma	3	3	0	0
Other lymphoid malignancies	15	11	3	1

Figure 1. The rates of antiemetic efficacy endpoints. Total control (TC), complete response (CR) and complete protection (CP) in early, delay and overall phase (A) in all patients (n = 82) and (B) in patients receiving full-dose ESHAP (n = 61).

Figure 2. The proportion of patients with emetic episodes (vomiting and nausea ≥ grade 2) on days 1 through 10 in all patients (n = 82).